300 related articles for article (PubMed ID: 16536995)
1. [Expression and clinical significance of apoptosis-related oncogenes in stage I-II non-small cell lung cancer].
Wang DF; Zeng CG; Lin YB; Hou JH; Zhu ZH
Ai Zheng; 2006 Mar; 25(3):359-62. PubMed ID: 16536995
[TBL] [Abstract][Full Text] [Related]
2. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases.
Kren L; Brazdil J; Hermanova M; Goncharuk VN; Kallakury BV; Kaur P; Ross JS
Appl Immunohistochem Mol Morphol; 2004 Mar; 12(1):44-9. PubMed ID: 15163019
[TBL] [Abstract][Full Text] [Related]
4. [Microvessel density and expressions of survivin and vascular endothelial growth factor in non-small cell lung cancer and their correlations to clinicopathologic features].
Wang L; Li X; Li Y; Xue YW
Ai Zheng; 2005 Jul; 24(7):823-6. PubMed ID: 16004808
[TBL] [Abstract][Full Text] [Related]
5. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
6. [Upregulation of survivin in non-small cell lung cancer and its clinicopathological correlation with p53 and Bcl-2].
Han PH; Li XJ; Qin H; Yao J; DU N; Ren H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Aug; 25(8):710-3. PubMed ID: 19664395
[TBL] [Abstract][Full Text] [Related]
7. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
8. [Expression and prognostic value of survivin protein in early-stage non-small cell lung cancer].
Zhu ZH; Yang H; Fu JH; Hu Y; Ma Y; Wu QL; Rong TH; Wang DF
Ai Zheng; 2007 Nov; 26(11):1268-71. PubMed ID: 17991331
[TBL] [Abstract][Full Text] [Related]
9. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
[TBL] [Abstract][Full Text] [Related]
10. [Expression of survivin and its clinical significance in non-small cell lung cancer].
Ren YJ; Zhang QY
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 37(5):504-7. PubMed ID: 16224523
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between combined multigene detection and response to adjuvant chemotherapy in early-stage non-small cell lung cancer].
Pan H; Li L; Zuo CT; Mao NQ; Chen FL; Zhang W; Tang BJ
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):528-31. PubMed ID: 19062721
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
[TBL] [Abstract][Full Text] [Related]
14. Apoptotic regulators: P53 and survivin expression in non-small cell lung cancer.
Porebska I; Sobańska E; Kosacka M; Jankowska R
Cancer Genomics Proteomics; 2010; 7(6):331-5. PubMed ID: 21156966
[TBL] [Abstract][Full Text] [Related]
15. Influence of survivin and Bcl-2 expression on the biological behavior of non-small cell lung cancer.
Gao Q; Yang S; Kang MQ
Mol Med Rep; 2012 Jun; 5(6):1409-14. PubMed ID: 22446832
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
17. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
[TBL] [Abstract][Full Text] [Related]
18. [Expression of granulocyte colony stimulating factor in patients with non-small cell lung cancer and its clinicopathological significance].
Wei LX; Chang WL; Guo AT; Tai YH; Sun L; Shi HY
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):721-5. PubMed ID: 22336152
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
20. [Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma].
Chen QY; Jiang ZY; Wu LJ; Zhang BY; Lu GH; Zhou JY
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):278-82. PubMed ID: 20510079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
